--- title: "Alterity Therapeutics (ATH) stock: news and investor profile" url: "https://aibio.space/companies/alterity-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Alterity Therapeutics Ltd. (ASX: ATH), Australia. The directory classifies it as Pharmaceuticals: Major." --- ATH Alterity Therapeutics Ltd. ASX · Australia # Alterity Therapeutics (ATH) news Listings · 2026-07-30 ## [Alterity reports A$37.3 million cash after 1-for-50 share consolidation](https://aibio.space/news/alterity-reports-37-3-million-cash-after-1-50-share-consolidation/) The quarterly cash flow report also shows an A$3,982,992 tax incentive refund and says the company is evaluating strategic and funding alternatives. ## Latest Alterity Therapeutics news 1. 2025-10-31 Financings [Alterity reports A$54.56M cash after A$20M placement in the quarter](https://aibio.space/news/alterity-reports-54-56m-cash-after-20m-placement-quarter/) Operating cash outflows were A$5.34M for the quarter ended 30 September 2025. The company says the placement was led by healthcare-focused funds. ## Alterity Therapeutics at a glance - **Ticker**: ATH - **Listing**: ASX - **Country**: Australia ### Related companies - [Invion](https://aibio.space/companies/invion/) ASX: IVX - [Immuron](https://aibio.space/companies/immuron/) ASX: IMC - [PYC Therapeutics](https://aibio.space/companies/pyc-therapeutics/) ASX: PYC - [Neurizon Therapeutics](https://aibio.space/companies/neurizon-therapeutics/) ASX: NUZ - [Epsilon Healthcare](https://aibio.space/companies/epsilon-healthcare/) ASX: EPN - [Anatara Lifesciences](https://aibio.space/companies/anatara-lifesciences/) ASX: ANR - [Calmer Co International](https://aibio.space/companies/calmer-international/) ASX: CCO - [Patrys](https://aibio.space/companies/patrys/) ASX: PAB ### Also on ASX - [Mayne Pharma Group](https://aibio.space/companies/mayne-pharma/) MYX - [AdAlta](https://aibio.space/companies/adalta/) 1AD - [Island Pharmaceuticals](https://aibio.space/companies/island-pharmaceuticals/) ILA - [Immutep](https://aibio.space/companies/immutep/) IMM - [Invex Therapeutics](https://aibio.space/companies/invex-therapeutics/) IXC - [CSL](https://aibio.space/companies/csl/) CSL ## What Alterity Therapeutics does Alterity Therapeutics Ltd. is an Australian company, incorporated on November 11, 1997, that develops first-in-class therapies for neurodegenerative diseases. Its technology centers on compounds that redistribute excess labile iron in the central nervous system, and on platform compounds that target the interaction of metals and proteins implicated in disease. Its lead drug candidate, ATH434, is an oral iron chaperone that has been shown in preclinical animal studies to reduce the accumulation and aggregation of alpha-synuclein. Its clinical development program is focused on multiple system atrophy (MSA), a rare Parkinsonian disorder with no approved treatments. The company has also conducted a Natural History Study in MSA and has a preclinical program in Parkinson's disease. Its chemical library includes more than 1000 novel compounds. The company also describes next generation zinc ionophores, invented in 2021, that may modulate zinc for diseases such as cancer, neurological diseases and infectious diseases. Its chemistry program is undertaken within laboratories leased from The University of Melbourne's Bio21 Molecular Science and Biotechnology Institute. | Product or program | What it is | Stage | |---|---|---| | ATH434 | Oral iron chaperone for MSA and Parkinson's disease | clinical development in MSA | | Parkinson's disease program | Iron chaperone compounds for Parkinson's disease and related disorders | preclinical | Summarised from the company's [20-F filed Aug 28, 2026](https://www.sec.gov/Archives/edgar/data/1131343/000143774926029135/athe20260630_20f.htm). ## Questions about Alterity Therapeutics What is the ticker symbol of Alterity Therapeutics? Alterity Therapeutics Ltd. trades under the ticker ATH on ASX. Where is Alterity Therapeutics listed? Alterity Therapeutics Ltd. is listed on ASX. Our directory also records these other listings: LS:A2PHDZ; NASDAQ:ATHE; OTC:PRNAF. What is the SEC CIK of Alterity Therapeutics? The SEC Central Index Key (CIK) for Alterity Therapeutics Ltd. is 1131343. Its filings are on SEC EDGAR. How many shares does Alterity Therapeutics have outstanding? 217,508,862 shares as of 2026-06-30, per the cover page of its 20-F filed 2026-08-28. Which country or territory is Alterity Therapeutics listed under? Our directory records Alterity Therapeutics Ltd. under Australia. What does Alterity Therapeutics do? Our directory classifies Alterity Therapeutics Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Alterity Therapeutics? The ISIN recorded for Alterity Therapeutics Ltd. is AU0000043945. Does aibio.space cover Alterity Therapeutics? aibio.space lists Alterity Therapeutics Ltd. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Alterity Therapeutics incorporated? SEC records list its state or country of incorporation as C3. What does Alterity Therapeutics develop? Alterity Therapeutics Ltd. is an Australian company, incorporated on November 11, 1997, that develops first-in-class therapies for neurodegenerative diseases. Its technology centers on compounds that redistribute excess labile iron in the central nervous system, and on platform compounds that target the interaction of metals and proteins implicated in disease. What is ATH434 from Alterity Therapeutics? ATH434: Oral iron chaperone for MSA and Parkinson's disease Stage: clinical development in MSA. What is Parkinson's disease program from Alterity Therapeutics? Parkinson's disease program: Iron chaperone compounds for Parkinson's disease and related disorders Stage: preclinical. What is the latest Alterity Therapeutics (ATH) stock news? Our latest story on Alterity Therapeutics, dated Jul 30, 2026: "Alterity reports A$37.3 million cash after 1-for-50 share consolidation". The quarterly cash flow report also shows an A$3,982,992 tax incentive refund and says the company is evaluating strategic and funding alternatives. [Source](https://aibio.space/news/alterity-reports-37-3-million-cash-after-1-50-share-consolidation/). What is Alterity Therapeutics's latest stock offering or financing news? Our latest financing story, dated Oct 31, 2025: "Alterity reports A$54.56M cash after A$20M placement in the quarter". Operating cash outflows were A$5.34M for the quarter ended 30 September 2025. The company says the placement was led by healthcare-focused funds. [Source](https://aibio.space/news/alterity-reports-54-56m-cash-after-20m-placement-quarter/). How long will Alterity Therapeutics's cash last? From our story of Jul 30, 2026: The company marked its three going-concern questions as N/A. The form requires those answers only where the estimated funding is less than two quarters. [Source](https://aibio.space/news/alterity-reports-37-3-million-cash-after-1-50-share-consolidation/). ## Investor discussion: Alterity Therapeutics Members talk about Alterity Therapeutics (ATH). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Alterity Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-07-30 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1131343/000143774926024928/ex_995835.htm) 2. 2026-06-04 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1131343/000143774926019479/athe20260604_6k.htm) 3. 2025-10-31 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1131343/000121390025104376/ea026335501ex99-1_alterity.htm) 4. 2025-04-30 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1131343/000121390025037102/ea024013201ex99-1_alterity.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open ASX:ATH on TradingView](https://www.tradingview.com/symbols/ASX-ATH/). ## SEC filings and registration - **SEC name**: Alterity Therapeutics Ltd - **CIK**: 1131343 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ATHE (Nasdaq), PRNAF (OTC) - **State or country of incorporation**: C3 - **Fiscal year ends**: June 30 - **Filer category**: Non-accelerated filer - **Business address**: LEVEL 15, 500 COLLINS STREET, MELBOURNE, VIC 3000 - **Phone**: 61 3 9349 4906 - **Shares outstanding**: 217,508,862 as of 2026-06-30 (20-F filed 2026-08-28) - **Former names**: PRANA BIOTECHNOLOGY LTD ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1131343/000143774926033047/athe20261021c_6k.htm) filed 2026-10-21 - [6-K](https://www.sec.gov/Archives/edgar/data/1131343/000143774926033045/athe20261021_6k.htm) filed 2026-10-21 - [6-K](https://www.sec.gov/Archives/edgar/data/1131343/000143774926032871/athe20261019_6k.htm) filed 2026-10-19 - [6-K](https://www.sec.gov/Archives/edgar/data/1131343/000143774926032387/athe20261009_6k.htm) filed 2026-10-09 - [6-K](https://www.sec.gov/Archives/edgar/data/1131343/000143774926031946/athe20261005_6k.htm) filed 2026-10-05 - [6-K](https://www.sec.gov/Archives/edgar/data/1131343/000143774926031171/athe20260925_6k.htm) filed 2026-09-25 - [6-K](https://www.sec.gov/Archives/edgar/data/1131343/000143774926030992/athe20260922_6k.htm) filed 2026-09-23 - [6-K](https://www.sec.gov/Archives/edgar/data/1131343/000143774926030702/athe20260918_6k.htm) filed 2026-09-18 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001131343), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Alterity Therapeutics Ltd. is a public biotech or pharmaceutical company listed on ASX under the ticker ATH, recorded under Australia. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Alterity Therapeutics Ltd. - **Ticker**: ATH - **Listing**: ASX - **Country or territory**: Australia - **Business scope**: Pharmaceuticals: Major - **ISIN**: AU0000043945 - **Other listed symbols**: LS:A2PHDZ; NASDAQ:ATHE; OTC:PRNAF - **Last quote in directory**: 2026-10-22 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/ASX-ATH/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/alterity-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Alterity Therapeutics (ATH) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/alterity-therapeutics/